Drugs / KL003 Cell Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06280378 | Apr 2024 → Oct 2025 overdue | beta-thalassemia major | Kanglin Biotechnology (Hangzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KL003 Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06280378 ↗ |
| Modality | Cell therapy | “KL003 Cell Injection is autologous CD34+ stem cells transduced Ex Vivo with a lentiviral Vector encoding βA-T87Q-Globin.” NCT06280378 ↗ |
| Route | Intravenous | “Administered by intravenous infusion after myeloablative conditioning with busulfan.” NCT06280378 ↗ |